Aorto-iliac Occlusive Disease Treatment Market Size, Share & Trends Analysis Report, By Device Type (Endovascular Devices, Surgical Devices), By Procedure (Endovascular Procedures, Hybrid Procedures), By End-use (Hospitals), By Region, And Segment Forecas

Aorto-iliac Occlusive Disease Treatment Market Size & Trends

The global aorto-iliac occlusive disease treatment market size was estimated at USD 2.26 billion in 2025 and is projected to reach USD 3.36 billion by 2033, growing at a CAGR of 5.02% from 2026 to 2033. Aorto-Iliac Occlusive Disease (AIOD) is a condition where the large arteries in the abdomen and pelvis, specifically the aorta and iliac arteries, become narrowed or blocked, reducing blood flow to the legs.

The increasing prevalence of Peripheral Artery Disease (PAD) is one of the key factors driving the market's growth. According to the American Heart Association, Inc. article published in June 2023, Peripheral artery disease (PAD) affects an estimated 200 million people worldwide. It significantly contributes to developing Aorto-iliac Occlusive Disease (AIOD). The growing prevalence of PAD, driven by factors such as aging populations, diabetes, and smoking, has increased the need for effective treatments for AIOD. This rising demand drives the adoption of minimally invasive procedures, including iliac artery stenting and endovascular therapies, which help restore proper blood flow and alleviate symptoms like leg pain and limited mobility.

Increasing government initiatives drive the growth of the market. According to the Congress.Gov article published in June 2023, the U.S. government took a significant step toward enhancing early detection and management of Peripheral Artery Disease (PAD), a primary contributor to Aorto-Iliac Occlusive Disease, through the introduction of the Arterial and Venous Comprehensive (ARC) Act. This legislation proposes amendments to the Social Security Act, aiming to ensure that Medicare and Medicaid beneficiaries identified as high-risk can access PAD screening without incurring out-of-pocket costs. Covered diagnostic procedures include ankle-brachial index (ABI) tests and arterial duplex scans, critical for identifying PAD and assessing disease severity in the aorto-iliac region. Authorizing USD 6 million in annual funding from 2024 to 2028, the ARC Act seeks to improve early diagnosis and timely intervention, potentially reducing the burden of advanced occlusive conditions and boosting the demand for targeted treatment options such as iliac stenting and revascularization therapies. This initiative promotes preventive care and supports broader access to essential vascular health services.

Moreover, as per the American College of Cardiology Foundation. article published in February 2025, the Sustainable Cardiopulmonary Rehabilitation Services in the Home Act (H.R. 783), recently reintroduced, proposes to make the Medicare coverage for in-home cardiopulmonary rehabilitation services permanent. This legislative move is designed to enhance access to essential rehabilitation, especially for patients with mobility limitations or those residing in remote areas. Facilitating easier access to rehabilitation care, this initiative supports the effective management of peripheral artery disease (PAD) and related conditions, including Aorto-Iliac Occlusive Disease, ultimately improving patient outcomes and driving demand for advanced treatment options in the market.

Technological advancements in aorto-iliac occlusive disease (iliac disease) treatment drive the market's growth. For instance, in January 2025, Bentley Medical introduced the BeFlow iliac covered stent system at the Leipzig Interventional Course (LINC) 2025, marking a significant advancement in treating aorto-iliac occlusive disease. Designed to address complex iliac lesions, the BeFlow stent offers enhanced long-term patency and durability, aligning with European Society for Vascular Surgery guidelines that recommend covered stents for heavily stenosed or occluded iliac arteries. Available in diameters ranging from 7 to 10 mm and lengths of 37 and 57 mm, the BeFlow stent aims to provide a cost-effective alternative to bare metal stents, improving patient access to advanced vascular interventions.

Global Aorto-iliac Occlusive Disease Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and analyzes the industry trends in each sub-segment from 2021 to 2033. for this study, Grand View Research has segmented the global aorto-iliac occlusive disease treatment market report based on device type, procedure, end use, and region:

• Device Type Outlook (Revenue, USD Million, 2021 - 2033)
• Endovascular Devices
• Balloon Angioplasty Devices
• Atherectomy Systems
• Stents
• Self-Expanding Stents
• Balloon-Expandable Stents
• Covered Stent Grafts
• Bifurcated Aortic Stent Grafts
• Surgical Devices
• Procedure Outlook (Revenue, USD Million, 2021 - 2033)
• Endovascular Procedures
• Balloon Angioplasty
• Primary Stenting
• Kissing Stents
• Covered Stent Grafts
• Endovascular Aortic Repair (EVAR)
• Hybrid Procedures
• Open Surgical Procedures
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Outpatient Facilities
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more